Jason P. Frazier

Functional genomics identifies therapeutic targets for MYC-driven cancer

Masafumi Toyoshima, Heather L. Howie, Maki Imakura et al. · Proceedings of the National Academy of Sciences · 2012 · 252 citations · Full text

Medicine, Molecular Biology, Oncology +17

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Andrey Loboda, Michael Nebozhyn, Rich A. Klinghoffer et al. · BMC Medical Genomics · 2010 · 153 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Identification and validation of PDGF transcriptional targets by microarray-coupled gene-trap mutagenesis

Weisheng V. Chen, Jeffrey J. Delrow, Philip Corrin et al. · Nature Genetics · 2004 · 110 citations

Life Sciences, Genetics, Molecular Biology +14

A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor

Richard A. Klinghoffer, S-Bahram Bahrami, Beryl A. Hatton et al. · Science Translational Medicine · 2015 · 95 citations · Full text

Medicine, Oncology, Pharmacology +17

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

Serena Di Cosimo, Sriram Sathyanarayanan, Johanna C. Bendell et al. · Clinical Cancer Research · 2014 · 56 citations · Full text

Pharmacy, Oncology, Pharmacology +17